Movement disorders : official journal of the Movement Disorder Society · 2012
Multiple system atrophy-parkinsonism with slow progression and prolonged survival: a diagnostic catch.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Petrovic Igor N, Ling Helen, Asi Yasmine, Ahmed Zeshan, Kukkle Prashanth L, Hazrati Lili-Naz, Lang Anthony E, Revesz Tamas, Holton Janice L, Lees Andrew J
Аннотация
BACKGROUND: Multiple system atrophy (MSA) is a neurodegenerative disease leading to severe physical impairment, with a disease duration from onset to death of 6-9 years.
METHODS: The clinical and neuropathological features of 4 MSA cases with disease duration of 15 years or more were analyzed.
RESULTS: All patients presented with parkinsonism and had a mean latency of 11 years before the development of dysautonomia. Mean duration from onset of first symptoms to anterocollis, inspiratory stridor, and dysphagia was 9 years. Despite the limited levodopa response, all patients developed levodopa-induced dyskinesia.
CONCLUSIONS: Late appearance of dysautonomia is a favorable prognostic factor in MSA-P. Greater awareness of this uncommon "benign" subgroup of MSA will improve diagnostic accuracy and help to more accurately inform treatment options.
METHODS: The clinical and neuropathological features of 4 MSA cases with disease duration of 15 years or more were analyzed.
RESULTS: All patients presented with parkinsonism and had a mean latency of 11 years before the development of dysautonomia. Mean duration from onset of first symptoms to anterocollis, inspiratory stridor, and dysphagia was 9 years. Despite the limited levodopa response, all patients developed levodopa-induced dyskinesia.
CONCLUSIONS: Late appearance of dysautonomia is a favorable prognostic factor in MSA-P. Greater awareness of this uncommon "benign" subgroup of MSA will improve diagnostic accuracy and help to more accurately inform treatment options.